MGB Biopharma develops more effective antibiotic for C.Diff

Published: 22-Sep-2011

Clinical trials are scheduled for 2012


A Scottish biopharmaceutical firm is developing a new MRSA and Clostridium difficile (C.diff) treatment that it claims is more effective in killing and preventing C.diff than the commonly used vancomycin.

Researchers at Glasgow-based MGB Biopharma have hailed the MGB BP-3 antibiotic as ‘extremely promising’.

The firm has licensed the technology from the University of Strathclyde.

Presenting their findings at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, US, the team said clinical trials of MGB BP-3 are scheduled for 2012.

MGB Biopharma chief executive Dr Miroslav Ravic said: ‘We are very excited that MGB BP-3 shows such a promising response against this troublesome and difficult-to-treat infection.

‘We are committed to developing a specific oral drug for the treatment of Clostridium difficile infections in addition to the progress we are making with an IV drug against MRSA.’

You may also like